News | May 10, 2007

Feinberg Study: Almost Half DES Implants Off-Label

May 11, 2007 — Northwestern University in Chicago has published results of a one-year study of roughly 5,500 patients who underwent angioplasty for the insertion of drug-eluting stents (DES) — it was found that nearly half of those patients did not fit the standard, approved indications for use set by the FDA.

Published in the May 9 issue of JAMA, the study observed that at the one-year mark, absolute event rates for the occurrences of complications associated with DES implantation, such as clotting and even death, were virtually no different from patients who received DES under the FDA's indications for approved use. Furthermore, states Northwestern, the study also demonstrated durable efficacy in preventing re-narrowing of the artery.

"We set out to systematically evaluate and compare the frequency of use, the safety and the effectiveness of drug-eluting stents in off-label and untested use versus standard use," said Nirat Beohar, MD, department of cardiology at Northwestern Memorial Hospital and assistant professor of medicine at Northwestern University's Feinberg School of Medicine. "Our results showed that patients are receiving stents that are either off-label or untested nearly half of the time. And, we were pleasantly surprised to learn that these patients fared just as well as those who received the stents under standard use."

For the purposes of the study, off-label use meant that patients received the DES although they did not meet approved indications, and untested stents were those where the safety and effectiveness of the DES had not been established for the applied use or treatment.

The study reviewed records for 7,752 percutaneous coronary intervention treated patients from 140 hospitals and medical centers. Roughly 90 percent of those patients received DES. Of that lot, 84 percent received DES and no other devices. It was then determined that roughly 95 percent, or 5,541, of those patients either received standard, off-label and untested use for DES, and it was this subgroup that was examined and followed for the purpose of this study. The research measured in-hospital, 30-day and one-year outcomes in an observational, prospective and multicenter registry.

Related Content

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting| January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init